101 results about "Renal glomerulus" patented technology

The invention relates to the technical field of treatment of chronic diseases of old people, and discloses a metabolic characteristic-based medicine dosage optimization method for chronic diseases of old people. The method comprises the following steps: acquiring drug metabolism parameters (including a plasma concentration peak value, a half-life period curve and the like) and organ function data (including a hepatocyte metabolism rate, a glomerular filtration rate and the like) of a plurality of monitoring nodes, arranging the drug metabolism parameters and the organ function data into a time sequence input vector, and extracting a dynamic feature vector by using a time convolution network and an adaptive filter network; performing feature crossing, pharmacokinetic constraint correction and feature enhancement processing, performing fusion to generate a joint feature vector, inputting the joint feature vector into a dose decision model to obtain an adjustment coefficient, and generating a drug dose interval with a safety threshold in combination with a historical drug use record. According to the method, multi-dimensional data integration and dynamic modeling are realized, the accuracy and safety of chronic disease medication of old people are improved, and the method is suitable for individualized treatment.

The invention discloses a glomerular segmentation method based on multi-scale Mama and dynamic sampling, and relates to the technical field of medical images. According to the method, the input multi-scale features are efficiently represented by using a continuous state transition mechanism, the structural association information extraction capability among different scales is enhanced, in addition, the problem of geometric distortion in dynamic sampling is solved by introducing position coding into the dynamic sampling method and adding position constraint information, and the dynamic sampling efficiency is improved based on a U-Net model. An MS-Mama module is gradually added in the encoder stage, and an existing bilinear interpolation method is replaced by a position sensing dynamic sampling module; and then, serialized representation is performed on multi-scale features based on a selective state space mechanism, the dependence of Mama on specific scale features is reduced, the ability of extracting heterogeneous morphological features of lesion glomerulus is enhanced, the boundary positioning precision of lesion glomerulus is enhanced by adding position constraint information, and the geometric distortion problem in dynamic sampling is solved.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

A method and system for constructing a glomerular filtration rate estimation model, including: step 1: performing mRMR feature selection on the original data set, screening out the independent variable features, and using the transformed data set as the basic data set for subsequent modeling; step 2: constructing two linear regression models on the basic data set; step 3: performing sampling with replacement on the basic data set, and removing duplicate samples; step 4: training the set model on the N sampled data sets after removing duplicates in step 3, and obtaining its parameters: obtaining N temporary local models, and performing multivariate linear regression modeling on the N sampled data sets after removing duplicates according to the above two forms obtained in step 2; step 5: constructing a global model, using the average of the local model parameters obtained in step 4 as the parameters of the global model, and the obtained global model is the constructed glomerular filtration rate estimation model. The present invention models data for a specific population and obtains a GFR estimation model that is more suitable for the specific population.

The invention relates to the technical field of glomerular pathological section cell detection, and discloses a cell detection method and system for a glomerular pathological section image, and the method and system are used for dynamically adjusting a detection threshold value based on the morphological characteristics of cells in the glomerular pathological section image so as to solve the problem that the cell boundary is fuzzy. The contrast enhancement degree is regulated and controlled according to the non-uniform illumination characteristic of the image, so that the detail loss area in the low-quality image is optimized; adjusting classification model parameters according to different types of glomerular lesion features so as to reduce the probability of occurrence of false detection and missing detection; and setting the number of iterations of the segmentation algorithm according to the cell overlapping degree to realize complete separation of dense cells. Through the scheme of the embodiment of the invention, the problem of how to regulate and control the detection threshold value according to the morphological characteristics of the cells in the glomerular pathological section so as to solve the problem of fuzzy cell boundary can be solved, and the phenomena of false detection and missing detection are reduced by taking the lesion specific marker in the training data set as input guidance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The invention discloses a pathology grading method and device, a storage medium and a computer program product, and relates to the technical field of medical image processing.The pathology grading method comprises the steps that a light microscope image of renal biopsy is obtained, a preset glomerulus recognition model is used for detecting the light microscope image, and slice images of all glomerulus are obtained; according to the slice image, determining a proportion result of each type of glomerulus in the light microscope image; and determining a pathology grading result according to the proportion result and a preset pathology grading rule. According to the method and the device, the glomerulus in the biopsy image is automatically identified and classified, and automatic classification is carried out according to the clinical pathology classification standard, so that the workload of a clinician in pathology classification is reduced, and the accuracy and the efficiency of pathology classification are improved.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

The invention provides a light microscope kidney pathological image analysis method based on artificial intelligence, and relates to the technical field of image recognition, and the method comprises the steps: obtaining a multi-mode light microscope kidney pathological image; performing positioning analysis on the glomerular structure of the multi-mode light microscope kidney pathological image by using the target detection network to obtain a position prediction result; classifying the position prediction result by using a classification network to obtain a classification result; utilizing a semantic segmentation network to perform pathological feature quantitative extraction on the complete glomerulus in the classification result to obtain a quantitative pathological index; and performing multi-level feature fusion on the classification result and the quantitative pathological indexes, and analyzing the obtained multi-level fusion features by using a multi-instance learning network of hierarchical attention to obtain a multi-modal light microscope kidney pathological image analysis result, thereby completing analysis of the light microscope kidney pathological image. The problem that an existing artificial intelligence method is difficult to accurately quantify the light microscope kidney pathological image is solved.

The invention discloses application of a pharmaceutical composition in preparation of a medicine for treating nephropathy, the nephropathy is at least one of membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and the pharmaceutical composition belongs to the technical field of pharmacy. The pharmaceutical composition is prepared from the following flavonoid components in a mass ratio: the mass ratio of the gossypothelin-8-O-beta-D-glucuronide to the hyperoside to the isoquercitrin to the myricetin to the quercetin-3 '-O-glucoside is 10 to (3.0 to 20) to (2.0 to 18) to (0.2 to 6.0) to (1 to 20). The pharmaceutical composition has obvious effects of preventing and / or treating membranous glomerulonephritis, postoperative acute kidney injury caused by non-contrast agents, immunoglobulin A nephropathy, purpura nephritis and idiopathic focal segmental glomerulosclerosis, and has relatively good safety.

The invention provides a basement membrane sampling method based on glomerular capillary branch characteristics, and relates to the technical field of image recognition, and the method comprises the steps: employing the center and radius of a glomerular region, carrying out the analysis of the mesangial crossing condition of a basement membrane, obtaining a mesangial crossing result, carrying out the region division and sampling window size calculation, and carrying out the calculation of the size of a sampling window. Obtaining a plurality of sectors and corresponding window areas; random sampling is carried out in the sectors to obtain candidate center points; analyzing the candidate center point based on the window area, if the sampling is not qualified, performing failure retry and annealing strategy to adjust the window, and resampling; otherwise, obtaining a qualified window; and combining all qualified windows to obtain a basement membrane sampling result, and completing the basement membrane sampling based on the glomerular capillary branch characteristics. According to the method, the problem of how to perform balanced, low-deviation, reproducible and efficient sampling and labeling on the glomerular basement membrane under the anatomical priori constraint in the light microscope glomerular pathological image is solved.

The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The present invention relates to a pharmaceutical composition for treating diabetic nephropathy, wherein the composition comprises a screened cobra cardiotoxin having a specific amino acid sequence. The diabetic nephropathy (DKD) refers to chronic kidney disease caused by diabetes. The composition can reduce the urine albumin / creatinine ratio (UACR) of diabetic nephropathy and improve the estimated glomerular filtration rate (eGFR).

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for preventing and treating hyperuricemia, which is prepared from the following raw materials by weight: 5-20g of gynostemma pentaphyllum, 10-20g of selaginella doederleinii hieron, 5-15g of berchemia lineate, 5-15g of parthenocissus parvifolia, 12-15g of lotus leaf, 12-15g of cassia seed, 12-15g of white paeony root and 3-6g of raw liquorice. The traditional Chinese medicine composition has no obvious influence on the normal blood sugar level, has stable hypoglycemic activity when being used by diabetes patients, cannot reduce the normal blood sugar state when being taken, can reduce the uric acid level, protect the kidney, improve the glomerular filtration rate and promote uric acid excretion, and can effectively treat, inhibit or prevent hyperuricemia.

The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).

The invention provides application of histone methyltransferase EZH2 as a therapeutic target of diabetic nephropathy podocyte senescence and injury, and relates to the technical field of biological medicine. It is found that the expression level of EZH2 in podocyte under the high glucose condition is remarkably increased, and conditions are provided for taking EZH2 as a biomarker for diagnosing or evaluating diabetic nephropathy podocyte damage and senescence. Subsequently, it is verified that podocyte damage of db / db mice can be remarkably improved, proteinuria of the db / db mice can be reduced, pathological damage of kidneys can be relieved, glomerular senescence of the db / db mice can be delayed, damage and senescence of podocytes under the high-glucose condition can be remarkably improved, the purpose of protecting the kidneys is achieved, the development of diabetic nephropathy is delayed, and the development of diabetic nephropathy is delayed. Therefore, the EZH2 can be used as a potential target for treating diabetic nephropathy.

The fragment omics features provide various properties of a sample (e.g., urine or plasma) and / or a subject. The relative contribution or enrichment of clinically relevant DNA (e.g., the type of renal and non-renal urine cfDNA) is provided utilizing the fragment omics characteristics of urine free DNA. Such measurements may be used to reflect glomerular permeability and to monitor various diseases, such as kidney abnormalities. The fragmenomics characteristics may include corrected urine DNA concentration, length, terminal motif of the urine DNA molecule, and cfDNA molecules from open chromatin regions (OCRs) of one or more tissues. Furthermore, the nuclease activity or other fragmentation process of the cfDNA is determined based on the relative contributions associated with different cfDNA cleavage profiles, which are also used to determine the contribution, pathological grade and gestational age of the cfDNA from the tissue.

The present invention relates to a composition for the prevention or treatment of lupus or glomerulonephritis, comprising a recombinant stable galectin 9 protein, and specifically, the recombinant stable galectin 9 protein of the present invention can be used in the prevention or treatment of systemic lupus erythematosus; the present invention shows safety in an SLE animal model, reduces skin lesions, lymphadenectasis and proteinuria caused by lupus, alleviates lupus nephritis and glomerulonephritis, reduces the concentration of anti-dsDNA antibodies in plasma, and provides a new means for treating lupus nephritis and glomerulonephritis. Therefore, the recombinant stable galectin 9 protein of the present invention can be effectively used as an active ingredient of a composition for preventing or treating lupus or glomerulonephritis.

The invention belongs to the field of medicine models, and provides a method for constructing a diagnosis model of glomerular crescent bodies of lupus nephritis patients. Comprising the steps of target collection data acquisition, statistical data analysis, inter-group comparison, biological index importance calculation and screening, candidate variable secondary screening, crescent body diagnosis model construction and crescent body diagnosis column graph construction. According to the method, the XGBoost algorithm is utilized to perform initial screening on the pre-prepared variables, and then the unconditional logistic gradual forward regression analysis is utilized to perform secondary screening, so that reliable screening of the crescent marker variables is realized, and in addition, the screening efficiency of the variables is improved; by converting the crescent body diagnosis model into the crescent body diagnosis column diagram, the crescent body diagnosis process is simplified, and the intuition of the model is improved.

The invention belongs to the technical field of disease drug treatment, and particularly relates to application of a CLK2 inhibitor in preparation of a drug for treating IgA nephropathy. The CLK2 inhibitor (such as ganoderic acid A methyl ester) can be used for remarkably reducing the levels of 24h UTP, 24h mAlb, BUN and Scr of an IgA nephropathy model and IGA deposition in glomerulus, so that the aim of effectively treating the IgA nephropathy is fulfilled.

This invention belongs to the field of renal pathology testing technology and discloses a method for detecting type IV collagen expression in renal biopsy tissue, comprising the following steps: dewaxing and hydrating paraffin sections of renal biopsy tissue to obtain processed tissue sections; adding the processed tissue sections to a repair solution, heating to boiling, and then cooling to room temperature to obtain repaired tissue sections; adding protease to the repaired tissue sections for enzymatic digestion to obtain enzymatically digested tissue sections; adding a primary antibody to the enzymatically digested tissue sections for preliminary incubation, followed by adding a fluorescein-labeled secondary antibody against the primary antibody for further incubation. This method for detecting type IV collagen expression in renal biopsy tissue is applicable to cases where renal biopsy tissue lacks glomeruli or has too few glomeruli to detect type IV collagen expression. It has high specificity and can provide a new detection method for Alport syndrome in cases where renal biopsy tissue lacks glomeruli.

The application discloses a pathological grading method and device, a storage medium and a computer program product, relates to the technical field of medical image processing, and relates to the technical field of medical image processing. The pathological grading method comprises the following steps: acquiring a light microscope image of a kidney biopsy, and detecting the light microscope image by using a preset glomerulus recognition model to obtain a section image of each glomerulus; according to the section image, determining a proportion result of each type of glomerulus in the light microscope image; and according to the proportion result and a preset pathological grading rule, determining a pathological grading result. The application automatically identifies and classifies the glomerulus in the biopsy image, and automatically classifies according to the clinical pathological grading standard, thereby reducing the work load of the clinician in the pathological grading, and improving the accuracy and efficiency of the pathological grading.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).

The invention provides a traditional Chinese medicine preparation for treating type 2 diabetic nephropathy and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine reagent is characterized by comprising the following raw materials: astragalus membranaceus, prepared rehmannia root, dogwood, salvia miltiorrhiza, safflower, poria cocos, rhizoma alismatis, prepared rhubarb, codonopsis pilosula and winged euonymus twig. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, tonifying kidney and removing turbidity through cooperation of the medicines. The whole formula focuses on the pathogenesis of deficiency stasis and turbid toxin, and the treatment effect is achieved through multiple target points and multi-layer effects. Animal experiments show that the preparation can significantly relieve glomerular mesangial matrix hyperplasia and renal interstitial fibrosis. Clinical experiments show that traditional Chinese medicine symptom scores and curative effects are reduced, blood sugar is controlled, and laboratory indexes related to renal functions are improved.